Press Release

Agenus to Present at Two Healthcare Investor Conferences In September

September 19, 2017

LEXINGTON, Mass., Sept. 19, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare investment conferences in September. The details for the conferences are:

  • Garo Armen, PhD, Chairman and CEO of Agenus, and Jennifer Buell, PhD, Chief Communications and External Affairs Officer will present at the Cantor Fitzgerald Global Healthcare Conference on September 25 at the InterContinental Barclay Hotel in New York. Corporate presentation at 4:10 p.m. ET.
  • Michael Plater, PhD, Chief Business Officer, and Jennifer Buell, PhD, Chief Communications and External Affairs Officer will present at the Ladenburg Thalman 2017 Healthcare Conference on September 26 at the Sofitel Hotel in New York. Corporate presentation at 1 p.m. ET.

Agenus Logo

A live audio webcast will be available on the "Events & Presentations" section of the Company's investor website at where a replay will also be available following the presentation.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA.  For more information, please visit; information that may be important to investors will be routinely posted on our website.


Agenus Inc. 
Jennifer Buell, PhD


SOURCE Agenus Inc.